High-Sensitivity Cardiac Troponin and the 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guidelines for the Evaluation and Diagnosis of Acute Chest Pain

Abstract

The 2021 American Heart Association/American College of Cardiology/American Society of Echocardiography/American College of Chest Physicians/Society for Academic Emergency Medicine/Society of Cardiovascular Computed Tomography/Society for Cardiovascular Magnetic Resonance guidelines for the evaluation and diagnosis of acute chest pain make important recommendations that include the recognition of high-sensitivity cardiac troponin (hs-cTn) as the preferred biomarker, endorsement of 99th percentile upper reference limits to define myocardial injury, and the use of clinical decision pathways, as well as acknowledgment of the uniqueness of women and other patient subsets. Details on how to integrate hs-cTn into clinical practice are less extensively addressed. Clinicians should be aware of some of the analytical aspects related to hs-cTn assays regarding the limit of detection and the limit of quantitation and how they are used clinically, especially for the single sample strategy to rule out acute myocardial infarction. Likewise, it is important for clinicians to understand issues related to the derivation of the 99th percentile upper reference limit; the value of sex-specific 99th percentile upper reference limits; how to use changing concentrations (deltas) to facilitate diagnosis and risk stratification of patients with suspected acute coronary syndrome, including the differentiation of acute from chronic myocardial injury; and how to best integrate the use of hs-cTn with clinical decision pathways. With the use of hs-cTn, conditions such as type 2 myocardial infarction become more common, whereas others such as unstable angina become less frequent but still occur. Sections relating to these issues are included.

Serum NfL and GFAP are associated with incident dementia and dementia mortality in older adults: The cardiovascular health study

“…Blood‐based biomarkers of neurodegeneration are potentially critical tools in the global fight against Alzheimer's disease (AD) and related dementias 1 . As neurodegenerative biomarkers, these analytes are not necessarily specific for a single pathophysiology but, as markers of neuronal injury and death, may provide predictive and staging information across dementia subtypes, analogous to the broad use of high‐sensitivity troponin as a biomarker of myocyte damage in cardiac disease 2 . Moreover, if shown to predict future incidence of dementia among individuals at risk, biomarkers of preclinical disease could assist in recruitment to future preventive trials that may enable disease‐modifying intervention prior to a critical loss of neurons.…”

Early Changes in Acute Myocardial Infarction in Pigs: Achieving Early Detection with Wearable Devices

“…These data will dramatically increase the sample size for analyzing the diagnosis threshold for AMI. For example, the 2022 American Heart Association/American College of Cardiology guidelines for chest pain diagnosis indicated detecting changes in troponin levels in the very early stage of AMI is difficult [ 37 ]. This is due, in part, to the lack of sufficient sample size.…”

Associations of Cardiac Biomarkers With Peripheral Artery Disease and Peripheral Neuropathy in US Adults Without Prevalent Cardiovascular Disease

“…[39][40][41] hs-troponin I is strongly associated with ischemic heart disease and other markers of end organ damage. 6,11,13 hs-troponin assays are the preferred biomarker by the American Heart Association for the detection of myocardial injury, 42 and both hs-troponin T and hs-troponin I are indicative of cardiomyocyte injury or necrosis. Prior studies have demonstrated that hs-troponin T and hs-troponin I are strongly associated with major adverse cardiovascular events, mortality, and rapid progression to symptomatic heart failure in asymptomatic adults.…”